One already is up nicely on its results, while the other two should issue reports of interest in the next few days.
I still believe it will be a big year for buyouts across the biotech industry.
Prices have moved above the early January high giving us the simple definition of an uptrend.
With cash levels high, those players who are not well-positioned for upside action are scrambling to put money to work and are helping to propel prices higher.
Despite the January rally, this biotech name and building materials firm still have further to rise.
These high risk/high reward oncology names look significantly undervalued, right now.
Let's check out the charts and indicators for a strategy that looks to balance risk and reward.
Allergan could move higher but some sort of retest of the December low seems in order in the short to intermediate term.
These companies are working to plant their flag in a new landscape.
I would add to them on any significant dips in the market.